
STOK • NASDAQ
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold STOK in your mock portfolio yet.
With a positive EPS of 0.68 and a relatively high PE ratio of 46.68, Stoke Therapeutics appears to be valued as a growth-oriented biotech with emerging, but not yet mature, earnings power. Profitability exists on a per-share basis, but the valuation suggests investors are pricing in substantial future growth rather than current fundamentals. Overall, the financial picture is more about expectations than established, stable profitability.
The stock trades at $31.74, modestly higher over the last month (+2.2%), and sits well above its 200-day moving average of $18.32, indicating a strong intermediate-term uptrend. An RSI of 54.09 is neutral-to-slightly-positive, suggesting neither overbought nor oversold conditions and leaving room for further upside if positive catalysts emerge. Overall, price action and trend metrics lean constructive.
Website traffic is flat at roughly 14,754 monthly visitors, suggesting no recent surge in retail or professional interest via the company’s site. Job openings at 14, down 12.5% month over month, may indicate a cautious hiring stance or a normalization after prior expansion, rather than aggressive growth. Social media presence is modest but growing slowly, with LinkedIn followers up 2.0% in 90 days and Twitter/X essentially flat, pointing to stable but not rapidly accelerating external engagement.
Stoke Therapeutics shows a strong technical uptrend and a growth-oriented valuation, supported by positive EPS but with fundamentals that appear more expectation-driven than firmly established. Alternative data are broadly stable, without strong signals of either accelerating momentum or deterioration in interest or hiring. Overall, the balance of evidence points to a neutral stance, with upside tied to execution and clinical or regulatory catalysts rather than current operational metrics.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: